Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE